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Results Among 195 patients who achieved pCR, 18 
developed recurrence. Furthermore, local recurrence 
occurred in 1.5% of patients (3/195), while distant metas-
tases occurred in 7.7% of patients (15/195), which included 
7 lung metastases, 1 liver metastasis, and 8 metastases in 
other locations.
Conclusions Our study indicated that patients achieving 
pCR following neoadjuvant CRT have a favorable prog-
nosis, with distant metastases predominating in all recur-
rences. Among patients with distant metastases, non-liver 
metastases were the predominant pattern.




AJCC  American Joint Committee on Cancer
APR  Abdominoperineal resection
AWD  Alive with disease
Cape  Capecitabine
chemo  Chemotherapy
CI  Confidence interval
CRM  Circumferential resection margin
CRT  Chemoradiotherapy
CT  Computed tomography
DOD  Died of disease
F  Female
FOLFOX6  5-FU, leucovorin, oxaliplatin
LAR  Low anterior resection
LN  Lymph nodes
LPLD  Lateral pelvic lymph node dissection
LPLN  Lateral pelvic lymph node
M  Male
MRI  Magnetic resonance imaging
Abstract 
Purpose The aim of this study was to characterize the 
patterns of recurrence in patients achieving pathologic 
complete response (pCR) after neoadjuvant chemoradio-
therapy (CRT) for locally advanced rectal cancer.
Methods Patients with locally advanced rectal cancer 
treated with neoadjuvant CRT and who achieved pCR from 
January 2004 to December 2012 were collected. The pri-
mary outcome measurement was the patterns of recurrence.
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OS  Overall survival
Oxa  Oxaliplatin
pCR  Pathologic complete response
PET  Positron emission tomography
pN (n)  Number of lymph nodes retrieved
RFS  Recurrence-free survival
RT  Radiotherapy
Tar  Targeted therapy
TME  Total mesorectal excision
USPIO  Ultra-small paramagnetic iron oxide
XELOX  Capecitabine and oxaliplatin
Background
Preoperative chemoradiotherapy (CRT) has been used as 
the standard management strategy for locally advanced 
rectal cancer over the past decade (Sebag-Montefiore et al. 
2009; Roh et  al. 2009; Sauer et  al. 2004), improving the 
outcome of locally advanced rectal cancer (Maas et  al. 
2010; Rodel et al. 2005; Garcia-Aguilar et al. 2003). Treat-
ment response to neoadjuvant CRT is linked with onco-
logic outcomes (Park et  al. 2012). Fifteen to twenty per-
cent of patients with locally advanced rectal cancer might 
achieve pathologic complete response (pCR) after neoad-
juvant CRT, which is associated with favorable long-term 
outcome (Park et  al. 2012; Campos-Lobato et  al. 2011; 
Smith et al. 2010).
Studies reporting the patterns of recurrence in patients 
achieving pCR after neoadjuvant CRT are very limited. In 
this study, we investigated the patterns of recurrence in this 
subgroup of patients.
Patients and methods
We retrospectively reviewed patients with locally advanced 
rectal cancer treated with preoperative CRT followed by 
radical resection at the Sun Yat-Sen University Cancer 
Center and the Sixth Affiliated Hospital of Sun Yat-Sen 
University between January 2004 and December 2012. 
Patients who achieved pCR after CRT and those who 
developed recurrence were enrolled in the study.
Tumors were staged according to the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual 
(Edge and Compton 2010). We defined pCR as absence 
of viable adenocarcinoma cells in the surgical specimen 
(ypT0N0). Local and distant recurrence was defined as 
relapse within and outside the pelvis, respectively. Time 
to diagnosis was defined as the time between any initial 
abnormal findings on follow-up examination to clinical or 
histological confirmation of recurrence.
Pre-treatment staging, tumor location, details of neo-
adjuvant and adjuvant therapy, interval to surgery, type of 
surgery, number of lymph nodes (LNs) retrieved, site(s) 
of recurrence, and salvage treatment were extracted from 
medical records.
We excluded patients who were diagnosed with a non-
skin cancer within 5  years of the rectal cancer diagno-
sis, did not complete neoadjuvant CRT, and who did not 
undergo radical rectal resection.
Pre-treatment evaluation included digital rectal exami-
nation, chest and abdominal computed tomography (CT) 
scans, and endoscopic ultrasound and/or magnetic reso-
nance imaging (MRI) of the pelvis. Prior to treatment, the 
pathologists of each hospital confirmed that all enrolled 
patients had adenocarcinoma of the rectum. Patients were 
treated with CRT that involved radiotherapy and fluoroura-
cil (FU)-based chemotherapy. Surgery was generally per-
formed 4–10 weeks following completion of CRT accord-
ing to total mesorectal excision (TME) principles.
Patients were followed-up every 3  months for 2  years, 
every 6 months for the next 3 years, and annually thereaf-
ter. Evaluations consisted of physical examination, serum 
carcinoembryonic antigen levels, abdominal ultrasound, 
and chest radiography. Liver ultrasonography was carried 
out every 3 months. Chest, abdominal, and pelvic CT scans 
were performed every year for 5 years. Other investigations 
were performed when clinically indicated during follow-up.
Results
Our retrospective review determined that 771 patients with 
locally advanced adenocarcinoma of the rectum had under-
gone CRT followed by TME at the Sun Yat-Sen University 
Cancer Center and the Sixth Affiliated Hospital of Sun Yat-
Sen University between January 2004 and December 2012. 
Twelve patients were excluded due to concurrent distant 
metastasis, concurrent malignancy, or prior history of pel-
vic radiotherapy. An eventual 195 patients with ypT0N0 
pathology (i.e., achieved pCR) were enrolled in the present 
study; 18 developed recurrence. The characteristics of these 
18 patients are summarized in Table 1.
Three patients developed lateral pelvic sidewall recur-
rence. All recurrence occurred in the lower rectum (within 
5  cm from the anal verge), and pre-treatment CT scan 
detected lateral LN metastasis (Fig. 1). After preoperative 
CRT, the metastatic LN was decreased to 2 mm. Standard 
TME was performed without lateral pelvic LN dissection 
(LPLD). However, there was recurrence in the lateral pelvic 
LN (LPLN), where recurrence occurred in 2 and 1 patient 
within 1 and 3 years, respectively, from the time of surgery. 
Only one patient underwent examination for 12 LN.



























































































































































































































































































































































































































































































































































































































































































































































































































 J Cancer Res Clin Oncol
1 3
Distant metastases occurred in 7.7% of patients (15/195; 
median time to relapse: 14  months), including 7 lung 
metastases, 1 liver metastasis, and 8 metastases in other 
locations. In all but 2 patients, recurrence was 5 cm below 
the anal verge, and the median number of examined LN 
was 9 (range: 0–18). Four of seven lung metastases and one 
liver metastasis were histological confirmed. None of the 
patients had both local and distant recurrence.
Discussion
Following the introduction of TME and CRT, local failure 
rates after curative (R0) resection of locally advanced rec-
tal cancer have decreased dramatically (Sauer et al. 2004; 
Collette et  al. 2007; Wibe et  al. 2002). Previous studies 
have consistently demonstrated that patients with good 
response after CRT have better long-term outcomes (Gar-
cia-Aguilar et al. 2003; Park et al. 2012).
The AJCC and International Union Against Cancer rec-
ommend retrieving a minimum 12 LN to achieve appropri-
ate staging. However, several studies have reported lower 
LN yield in proctectomy specimens from patients treated 
with preoperative CRT (Fuente et  al. 2009; Marks et  al. 
2010; Govindarajan et  al. 2011). In the present study, we 
retrieved much fewer LN (median number of examined LN: 
8, range: 0–18) than previous reports of patients treated 
with neoadjuvant CRT. As has been previously reported, 
the number of LN harvested varies greatly even when 
surgical treatment and pathological evaluation have been 
standardized (Marks et al. 2010). At our hospitals, all colo-
rectal surgeons involved in this study had received formal 
training in TME, thus all patients in this group underwent 
surgical treatment involving adequate TME proctectomy. 
The inadequate LN sampling may suggest incomplete 
TME, which might result in adverse oncological outcome. 
However, some researchers were unable to identify any 
relationship between the reduced numbers of LNs exam-
ined and decreased patient survival (Rullier et  al. 2008; 
Ha et al. 2010). Moreover, a study by the Cleveland Clinic 
not only confirmed the association between neoadjuvant 
therapy and decreased number of LNs retrieved from proc-
tectomy specimens, but also suggested that the diminished 
number of LNs is actually an indicator of improved tumor 
response and consequently decreased local recurrence rates 
(Campos-Lobato et al. 2013).
LPLN metastasis is another reason for the local recur-
rence in our data. In the present study, the failure pat-
tern of the three cases raises the question of whether 
LPLD should be performed in patients with suspected 
LPLN metastasis based on pre-CRT CT or MRI, and how 
patients who may benefit from LPLD can be identified. 
Studies from Japan have demonstrated that the incidence 
of LPLN metastasis is approximately 15% in patients 
with advanced low rectal cancer who underwent LPLD, 
and varies from 10.6 to 25.5% (Konishi et al. 2010). The 
Fig. 1  Lateral pelvic recurrence on computed tomography. a Pre-
treatment image shows a 5-mm lymph node in the right obturator area 
(white arrow). b Patient underwent neoadjuvant chemoradiotherapy 
and the metastatic lymph node was decreased to 2 mm (white arrow). 
c Follow-up image at 12  months after surgery shows lateral pelvic 
recurrence (white arrow).
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major drawback is that the above mentioned results were 
obtained from patients who had not undergone preopera-
tive CRT. In the Western countries, the standard treat-
ment for patients with locally advanced rectal cancer is 
preoperative CRT followed by TME alone. LPLN metas-
tasis is generally considered a metastatic disease that is 
not amenable to surgical cure. Moreover, some studies 
have revealed that preoperative radiotherapy followed 
by TME led to acceptable local control that was as good 
as that achieved by extended surgery, which included 
LPLD (Georgiou et al. 2009; Quadros et al. 2012). Con-
sequently, it is widely accepted in the Western countries 
that routine LPLD is not necessary. However, several 
studies have revealed that selective LPLD might improve 
local control and survival in patients with LPLN metasta-
sis in advanced low rectal cancer who have been treated 
with preoperative CRT. Akiyoshi and colleagues showed 
that the rate of pathological LPLN metastasis was 66% 
when they performed pre-CRT LPLD based on LPLN 
size and that preoperative CRT alone could not eradicate 
LPLN metastasis completely, thus LPLD might improve 
local control and survival of patients with LPLN metas-
tasis in advanced low rectal cancer treated with preop-
erative CRT (Akiyoshi et al. 2014). Kim and colleagues 
showed that lateral pelvic recurrence is the most common 
pattern of local recurrence following neoadjuvant CRT 
plus TME alone and that patients with preoperative evi-
dence of LPLN metastasis could benefit from LPLD even 
after neoadjuvant CRT (Kim et  al. 2008). In our study, 
among the 195 patients who achieved pCR, CT scan or 
MRI detected lateral LN metastasis in ten patients with 
low rectal cancer, 3 (30%) of whom eventually devel-
oped lateral pelvic recurrence after follow-up. Although 
the evidence from our cohort is very limited, we agree 
with previous studies on the most common pattern of 
local recurrence, and that TME alone following preop-
erative CRT might be insufficient for controlling LPLN 
metastasis that is present before CRT. As suspicious 
metastatic LNs in the lateral pelvic area are a risk fac-
tor for local recurrence in patients who have undergone 
curative resection with preoperative concurrent CRT, and 
LPLD has been associated with increased morbidity such 
as blood loss, and urinary and sexual dysfunction, cor-
rect detection of LPLN is crucial. Previously, CT was the 
standard method for assessing the pre-treatment clinical 
nodal stage. Unfortunately, a meta-analysis (Bipat et  al. 
2004) reported only 55% sensitivity for LN involvement 
by CT staging. Consequently, more reliable imaging 
criteria for detecting LPLN metastasis are needed. Cur-
rently, newer techniques, e.g., MRI or positron emission 
tomography (PET) scanning are used to improve LN 
staging accuracy. Brown et  al. (2003) found that high-
spatial resolution MRI had a sensitivity of 85% [51/60 
(95% confidence interval, CI: 74%, 92%)] and a speci-
ficity of 97% [216/221 (95% CI: 95%, 99%)] for LN (+) 
defined by the presence of mixed signal intensity or irreg-
ular nodal capsule border. Koh and colleagues (Koh et al. 
2010) used ultra-small paramagnetic iron oxide (USPIO), 
a LN-specific biodegradable contrast agent with the 
potential to enable identification of nodal metastasis 
independently of LN size for MRI. They found that the 
USPIO enhancement pattern had higher diagnostic speci-
ficity, but the same sensitivity, as morphological findings 
in pathologically matched mesorectal LNs (specificity, 93 
vs. 75%; sensitivity, 65 vs. 65%). It appears that PET/CT 
is less accurate than MRI for LN staging (Farwell et  al. 
2014), but has higher specificity than MRI (83–85% vs. 
67%) in nodal staging (Kim et al. 2011; Cipe et al. 2013). 
Additionally, we believe that combined MRI and PET 
(fusion imaging) would increase the accuracy of nodal 
staging. Further studies are essential for identifying the 
most reliable imaging criteria for LPLN metastasis in 
patients treated with preoperative CRT.
The present study demonstrates that distant metasta-
ses are the major failure pattern of patients who achieve 
pCR after CRT, which is similar to the findings of pre-
vious reports (Table  2). Maas and colleagues reported 
a 5-year distant metastasis rate of 11.2% (Maas et  al. 
2010). Capirci and colleagues performed a long-term 
analysis of 566 patients who achieved pCR, reporting 
a distant metastasis rate of 8.9% after a 46-month fol-
low-up (Capirci et  al. 2008). The persistence of distant 
metastases suggests the inadequate systemic control of 
the CRT regimen. Thus, the high rate of distant failure 
may indicate that adjuvant chemotherapy is warranted in 
these patients. However, the role of postoperative CT fol-
lowing neoadjuvant CRT and radical surgery for patients 
with locally advanced rectal cancer is still not entirely 
clear, especially in patients with pCR. Some studies 
suggest that there is little or no benefit from chemother-
apy (Maas et  al. 2010; Capirci et  al. 2008; Kiran et  al. 
2012). However, Collette and colleagues (Collette et  al. 
2007) demonstrated that the administration of adjuvant 
Table 2  Outcomes of patients with pCR at other hospitals
pCR pathologic complete response






Capirci et al. (2008) 536 8.9 0.9
De Campos-Lobato et al. (2011) 54 10 0
Smith et al. (2010) 100 8 1
Yeo et al. (2010) 304 7.9 2.6
Current study 195 7.7 1.5
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chemotherapy was associated with significantly improved 
overall survival. Their study randomly assigned patients 
to adjuvant chemotherapy or no adjuvant chemotherapy 
after (chemo) radiation and surgery for rectal cancer. 
Patients with ypT0–2 tumors, but not ypT3–4 tumors, 
benefited from adjuvant chemotherapy; the authors 
explained that tumors that respond well to preoperative 
FU-based chemoradiation would also be sensitive to 
adjuvant chemotherapy involving this drug. These con-
trasting findings indicate that more trials involving adju-
vant chemotherapy following neoadjuvant CRT should be 
performed in future.
Consistent with previous reports, we also observed a 
unique pattern of distant recurrence, where there was a pre-
dominance of non-liver metastases. In our study, only one 
patient developed liver metastasis; extra-liver metastases 
involved seven lung metastases and two bone metastases. 
Different theories have been proposed to explain the pattern 
of metastases, although this process appears to be multi-
factorial (Ding et al. 2012). The “seed and soil” hypothesis 
states that, due to different organ-specific microenviron-
ments, tumors may metastasize to specific organs indepen-
dently from the vascular anatomy (Fidler 2003). However, 
some researchers suggest that tumors might metastasize to 
specific organs independently based on the differential level 
of thymidylate synthase (TS) mRNA, which causes dif-
ferential sensitivity to 5-FU-based chemotherapy. Patients 
with higher TS mRNA levels easily develop pulmonary 
metastasis (Yamada et  al. 2001). Such findings are also 
attributed to the nature of the venous drainage of the rec-
tum (Watanabe et al. 2011). Intensive surveillance schemes 
and improved imaging technology may also contribute to 
the high rate of lung metastasis detected, which is consist-
ent with that of previous studies (Kirke et  al. 2007; Lee 
et al. 2007).
There are some potential limitations to this study. The 
first lies in the limited number of enrolled patients, given 
their good outcomes. The second potential limitation is 
that the number of LNs retrieved was much lower than that 
in previous reports on patients treated with neoadjuvant 
CRT. However, the inadequate LN sampling in our study 
may have been due to improved tumor response. The third 
potential limitation involves regular assessment of the cir-
cumferential resection margin (CRM) status. The CRM is 
considered one of the strongest predictors of surgical fail-
ure in rectal cancer (Kelly et al. 2011). We do not routinely 
assess the CRM status, but the pathologists at our hospitals 
routinely perform macroscopic evaluation of rectal cancer 
resection specimens. The quality of the mesorectum is clas-
sified as good (mesorectal), intermediate (intramesorec-
tal), or poor (muscularis propria plane) (Quirke 2003). The 
mesorectum quality of the 18 patients included in our data 
was good, indicating smooth CRM on slicing.
In conclusion, our data demonstrate that distant metas-
tases are the major failure pattern of patients who achieve 
pCR after CRT and that non-liver metastases are the pre-
dominant pattern of distant recurrence. Our results indicate 
the possible predominant pattern of distant recurrence and 
serve as a basis for managing LPLN metastasis in low rec-
tal cancer. Patients with LPLN metastasis in advanced low 
rectal cancer treated with preoperative CRT would benefit 
from selective lateral LN excision.
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